MRK  Merck & Company Inc.

Exchange

NYSE

Sector

Consumer Durables

Industry

Major Pharmaceuticals

Market Cap.

170.1B

Vuru Grade

47.84/100

Current Price

$59.66
+0.32 (+0.54%)

Growth Price

$47.52
Overvalued by 20.35%

Stability Price

$23.65
Overvalued by 60.37%

Company Metrics

  • 32.30 P/E
  • 3.93 P/S
  • 3.75 P/B
  • 1.837 EPS
  • 10.80% Cash ROIC
  • 0.98 Cash Ratio
  • 1.76 / 2.97 % Dividend
  • 10.57M Avg. Vol.
  • 2.85B Shares
  • 170.1B Market Cap.

Company Description

Merck & Co., Inc. provides various health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. The company's Pharmaceutical segment provides human health pharmaceutical products, such as therapeutic and preventive agents for the treatment of human disorders in the areas of bone, respiratory, immunology, dermatology, cardiovascular, ...
more


Download 10 Years of Financial Statements:
Income Statement   Balance Sheet   Cash Flow

News

Merck buys rights to NewLink's experimental Ebola vaccine
Reuters - Nov 24, 2014
(Reuters) - Merck & Co Inc (MRK.N) on Monday said it would buy worldwide commercial rights to NewLink Genetics Corp's (NLNK.
Merck, Iowa's NewLink Genetics sign exclusive licensing deal for Ebola vaccine ... - Minneapolis Star Tribune
Merck & Co., Inc. Announces Quarterly Dividend of $0.45 (MRK)
Ticker Report - 19 hours ago
Merck & Co. logo Merck & Co. (NYSE:MRK) announced a quarterly dividend on Tuesday, November 25th, AmericanBankingNews.
Company Update (NYSE:MRK): Merck Announces Increased Quarterly Dividend - Jutia Group
Merck & Co., Inc. Tops Earnings, Misses Revenue Estimates
ValueWalk - Oct 27, 2014
Merck & Co., Inc. (NYSE:MKR) released the earnings results from its third quarter this morning before opening bell, posting adjusted earnings of 90 cents per share on $10.56 billion in revenue.
Merck & Co., Inc. (NYSE:MRK) Reports Results from Hepatitis C Treatment
Markets Wired - Nov 11, 2014
Merck & Co., Inc. (NYSE:MRK) reported Tuesday promising results from a multi-arm Phase 2 clinical trial evaluating grazoprevir/elbasvir, a product to treat the chronic hepatitis C virus genotype 1 in treatment-naive and previously-treated patients.
Merck Reports Interim Data on Hepatitis C Virus Drug - Yahoo News
Anti-PD-1 Drug Keytruda Gives Merck & Co. (MRK) Reason To Rejoice Again
Bidness ETC - Nov 19, 2014
Merck & Co., Inc. (NYSE:MRK) has announced positive Phase II trial results for its anti-PD-1 therapy Keytruda (pembrolizumab).
Medical Breakthroughs On The Horizon For Merck (MRK)
Seeking Alpha - Nov 20, 2014
Merck (MRK) is a global health care company that includes prescription medicines; vaccines, biologic therapies, animal health and consumer care products.
Merck & Co., Inc. (NYSE:MRK) Has Enlarges Firm's Quarterly Dividend To $0.45 ...
StreetWise Report - 1 hour ago
Merck & Co., Inc. (NYSE:MRK) [Detail Analytic Report] named as MSD outside the U.S. and Canada, proclaimed that the BOD has enlarged the firm's quarterly dividend to $0.45 per outstanding share of the firm's common stock, up $0.01 from $0.44 per ...
Pfizer Inc. (NYSE:PFE) and Merck & Co., Inc. (NYSE:MRK) Partners For Immuno ...
USMarketsDaily (blog) - 23 hours ago
Pfizer Inc. (NYSE:PFE) will pay $850 million to Merck & Co., Inc. (NYSE:MRK) as an upfront payment, under the terms of the agreement.
Interesting January 2017 Stock Options for Merck & Co.
Forbes - Nov 17, 2014
Consistently, one of the more popular stocks people enter into their stock options watchlist at Stock Options Channel is Merck & Co Merck & Co., Inc (NYSE: MRK). So this week we highlight one interesting put contract, and one interesting call contract ...
Interesting July 2015 Stock Options for Merck
Forbes - Nov 24, 2014
Consistently, one of the more popular stocks people enter into their stock options watchlist at Stock Options Channel is Merck & Co MRK -0.52%., Inc (NYSE: MRK). So this week we highlight one interesting put contract, and one interesting call contract ...